The latest research indicates that CLL cells have high levels of antiapoptotic BCL-2 protein to resist chemotherapy-induced cell death, suggesting that BCL-2 might be a potential target for CLL treatment. This evidence concerns the gene BCL2 and B-cell chronic lymphocytic leukemia.